ReviewPediatric research2025
G6PD trait: societal importance to ensure well-being of female heterozygotes for health and childbirth.
Review in Pediatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Universal newborn screening for G6PD deficiency and severe hyperbilirubinemia at a tertiary center in Jerusalem.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neonatal G6PD deficiency (G6PDd) prevalence explains its recent recognition as a major contributory cause of extreme hyperbilirubinemia (EHB). Disparate global EHB burden reveals comparative racial prevalence of leading conditions, Rh negativity and G6PDd: 15-17% vs. < 5% in Caucasians, 4 to 8% vs. up to 17% in Blacks and 0.1 to 4% vs. 5-8% in Asians, respectively. G6PDd also burdens malaria endemic countries planning malarial elimination. Binary expression of male G6PDd is reliably diagnostic but is complex and uncertain for heterozygous females. Unlike the RhD disease and its prevention, the medical and hematological life burdens of female G6PDd and heterozygosity have been vastly understudied. Three silent global health crises intersect: EHB, Malaria, and women's health. Regardless of race, sex, or geography, clinical practice needs optimization with dual (phenotypic and genotypic) screening to allow women plan and anticipate safe pregnancies, birthing, breastfeeding and enjoy their newborns' healthy childhood in a society freed of malaria.
Indexed as
Identifiers
39537762What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.